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ABSTRACT
Complete remission by induction therapy in acute myelogenous leukemia 
(AML) can be achieved due to improvements in supportive and optimized therapy. 
However, more than 20% of patients will still need to undergo salvage therapy, and 
most will have a poor prognosis. Determining the specificity of drugs to leukemia 
cells is important since this will maximize the dose of chemotherapeutic agents 
that can be administered to AML patients. In turn, this would be expected to lead 
to reduced drug toxicity and its increased efficacy. We targeted Notch-1 positive 
AML cells utilizing fucose-bound liposomes, since activation of Notch-1 is required 
for O-fucosylation. Herein, we report that intravenously injected, L-fucose-bound 
liposomes containing daunorubicin can be successfully delivered to AML cells that 
express fucosylated antigens. This resulted in efficient tumor growth inhibition in 
tumor-bearing mice and decreased proliferation of AML patient-derived leukemia 
cells. Thus, biological targeting by fucose-bound liposomes that takes advantage of 
the intrinsic characteristics of AML cells could be a promising new strategy for Notch-1 
positive-AML treatment.
INTRODUCTION
Approximately sixty percent of patients with acute 
myelogenous leukemia (AML) will achieve complete 
remission by induction therapy due to improvements 
in supportive, and increasingly optimized, therapy [1]. 
However, more than 20% of patients will still need 
to undergo salvage therapy, with most having a poor 
prognosis [2]. Based on such previous reports, determining 
the specificity of drugs to leukemia cells is important 
to improve a considerable proportion of AML patients’ 
prognoses, since minimizing the dose of administered 
chemotherapeutic agents would be expected to lead to 
reduced toxicity and increased efficacy.
Notch-1 is a homolog of the translocation-associated 
Notch homologue (TAN-1) discovered in the t(7;9)
(q34;q34) translocation in some T-cell acute lymphoblastic 
leukemia patients (T-ALL) [3]; its ligands are modified by 
a protein O-fucosyltransferase 1 (POFUT1) that attaches 
L-fucose to a serine or threonine within EGF domains 
[4, 5]. High expression of Notch-1 has been reported 
to be a predictive marker for a poor prognosis in AML 
patients [6] and is thus proposed as a therapeutic target 
in hematological malignancy [7, 8]. However, targeting 
Notch-1 by using an activator such as γ-secretase, or by 
the deletion of POFUT1, has been shown to result in 
gastrointestinal toxicity [9]. Therefore, directly targeting 
Notch-1 or the specific delivery of γ-secretase to Notch-
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positive leukemia cells is necessary to improve treatment 
strategies.
L-fucose is a monosaccharide that is a common 
component of many N- and O-linked glycans and 
glycolipids produced by mammalian cells [10]. As reported 
previously [11], we focused on the specific biological 
characteristics of metastatic pancreatic cancer, especially 
fucosylated antigens such as sialyl Lewis X (SLX) antigen 
and carbohydrate antigen-19-9 (CA19-9), which are found 
in the sera and tumor tissues of patients [12, 13] and are 
used as tumor markers in detecting cancer and in the 
evaluation of treatment efficacy. Furthermore, enhanced 
expression of fucosyltransferases (FUTs) has been reported 
in various cancers. FUTs are key enzymes accelerating 
malignant transformation through the fucosylation of 
different sialylated precursors. It has been reported that 
enhanced activity of FUT3 is associated with the increased 
metastatic potential of colon and pancreatic adenocarcinoma 
cells [14], suggesting that fucosylation may play an 
important role in disease progression. These observations 
indicate a high requirement for L-fucose by various cancer 
cells [15]. Indeed, we, together with others, have reported 
that enhanced FUT activity facilitated the metastatic 
potential of colorectal cancer cells, thus highlighting this as 
a therapeutic target for cancer therapy [16].
The siglecs (sialic acid-binding immunoglobulin 
superfamily lectins) are immunoglobulin superfamily 
members that recognize sialylated ligands [17]. Most prior 
studies of siglec specificities have focused on α 2–3- and α 
2–6-sialyllactos (amin)es, and on one or two of the siglecs 
at a time. Of the various existing siglecs, siglec-3 (CD33), 
which is expressed in AML patients, has been reported to 
be affected markedly by the presence of an α1–3-linked 
fucose. To target AML cells directly, therefore, CD33 
seems to be a promising molecule.
In this study, we targeted Notch-1 positive AML cells 
by utilizing fucose-bound liposomes, since activation of 
Notch-1 is required for O-fucosylation by POFUT. Herein 
we report that intravenously injected L-fucose-bound 
liposomes containing daunorubicin can be successfully 
delivered to AML cells that express fucosylated antigens. 
This resulted in efficient tumor growth inhibition in tumor-
bearing mice. Thus, biological targeting by fucose-bound 
liposomes utilizing characteristics intrinsic to AML cells 
could be a promising new strategy for AML treatment.
RESULTS
Expression of CD33 and Notch-1 in leukemia cell 
lines
We first analyzed the expression of CD33 and 
Notch-1 in various leukemia cell lines. As shown in Figure 
1A, the expression of CD33 was observed in all cell lines 
except for Molt4. It should be noted that RPMI8226 
cells, which were derived from a multiple myeloma, 
expressed an appreciable amount of CD33 as previously 
reported [18]. Notch-1 expression was also examined, 
being found in HL60, RPMI8226, and KG1 cells, but not 
in Molt4 cells. We then analyzed the mRNA expression 
of POFUT1 in various leukemia cells line (Figure 1B, 
1C, Supplementary Figure 1) and found that this directly 
correlated with Notch-1 expression. However, we did not 
observe a relationship between other FUTs and Notch-1 
expression (Supplementary Figure 1). Thus, the expression 
of CD33 and Notch-1 correlated in the same leukemia cell 
lines.
Targeting Notch-1 positive cells by fucose-bound 
liposomes
We then investigated whether Notch-1 positive 
leukemia cells could be targeted by L-fucose-bound 
liposomes. As reported previously [11], aminated 
L-fucose was cross-linked via 3,3´-dithiobis[sulfosuc
cinimidylpropionate] (DTSSP) to liposomes prepared 
by a modified cholate dialysis method to achieve a final 
concentration of 25 (F25) or 50 µg/ml (F50). Furthermore, 
bis(sulfosuccinimidyl)suberate (BS3) and Tris were then 
coupled to hydrophilize the liposome surface, which 
normally prevents uptake by the reticuloendothelial 
system in the liver and spleen, as well as by macrophages 
and vascular endothelial cells, and can also prevent 
adsorption to opsonin proteins in plasma; consequently, 
systemic retention of liposomes is prolonged [19]. 
Almost all L-fucose-bound liposomes (Fuc-Liposomes) 
were spherical in shape and, in the case of FAM- and 
daunorubicin, were approximately 70 – 100 and 170 nm, 
respectively, in size (Supplementary Tables 1 and 2). The 
zeta-potential, representing the negative electric charge of 
the liposome surface, was below -40 mV (Supplementary 
Tables 1 and 2), which meant it was sufficiently 
hydrophilized for stealth functions.
Using these Fuc-Liposomes, we added FAM 
encapsulated L-fucose-liposomes (Fuc-Liposome-FAM) 
to Notch-1 positive or negative leukemia cell lines to 
confirm the specificity of delivery. As shown in Figure 
2A, fluorescence microscopy revealed that F50-Fuc-
Liposomes, but not F0-Fuc-Liposomes, effectively 
introduced FAM into the cytosol of HL60 cells. However, 
Molt4 cells, which do not express Notch-1, did not show 
uptake of FAM. Furthermore, flow cytometry analysis 
showed that after 2 h of incubation, F50-Fuc-Liposomes, 
but not F0-Fuc-Liposomes, effectively introduced FAM 
into the cytosol of HL60 cells that expressed Notch-1 
(Figure 2B). Since we previously confirmed that uptake of 
L-fucose is mediated by its receptors [11], excess L-fucose 
decreased the efficiency of this process (data not shown), 
indicating that the introduction of FAM by Fuc-Liposomes 
is indeed L-fucose-dependent. Thus, Notch-1 positive 
leukemia cells were found to be targeted by L-fucose-
bound liposomes.
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Figure 1: Expression of POFUT1 in Notch1 positive cell lines. A. Flow cytometric analysis of HL60 and CD33 expression 
in leukemia cell lines HL60, RPM8226, KG1 and Molt4. Expression of POFUT1 mRNA in leukemia cells lines examined by semi-
quantitative B. and quantitative C. PCR. These experiments were performed three times.
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Effect of Fuc-Liposome-daunorubicin on the 
growth of leukemia cell lines
We then encapsulated daunorubicin into Fuc-
Liposomes. Fuc-Liposome- daunorubicin particles were 
approximately 170 nm in size, and the final concentration 
of daunorubicin was estimated at 1 mg/ml (Supplementary 
Table 2). This size of nanoparticle is postulated to allow 
penetration through the smallest capillary pores within 
the cancer vasculature by an enhanced permeability and 
retention (EPR) effect, but without breaching the blood-
brain barrier [20]. The cytotoxicity of Fuc-Liposome-
daunorubicin was tested using a BrdU cell proliferation 
assay (Figure 3). Cultured leukemia cells were exposed 
to Fuc-Liposome-daunorubicin or Liposome-daunorubicin 
for 2 h and then washed twice with phosphate-buffered 
saline to test the efficacy and specificity of daunorubicin 
transfer into Notch-1 positive cells. Because we 
observed the greatest cytotoxicity using F50-Liposome-
daunorubicin (50 µg/mL fucose; Figure 3), we selected 
this condition for the following experiments. In Notch-1 
positive cells (HL60, KG1), F50-Liposome-daunorubicin 
exerted more potent effects than control liposomes (F0-
Liposome-daunorubicin), indicating fucose-dependent 
cytotoxicity (Figure 3). In addition to the effects on 
Notch-1 leukemia cell lines, the growth of other cancers, 
such as pancreatic and biliary cancer cell lines which 
produce CA19-9, were effectively suppressed by F50-
Liposome-cisplatin, indicating the potential applicability 
of this nanoparticle technology for the treatment of 
different types of cancer (data not shown) [11]. Moreover, 
cytotoxicity was not seen in normal cells such as 
peripheral blood mononuclear cells, fibroblasts, human 
umbilical vein endothelial cells (HUVEC), or primary 
keratinocytes, probably due to their low requirement for 
L-fucose, as previously described [11]. Therefore, Fuc-
Liposome-daunorubicin particles were found to inhibit 
the growth of Notch-1 positive cells in vitro in a fucose-
dependent manner without affecting various normal cell 
types.
Fuc-Liposomes carrying daunorubicin 
suppressed tumor growth and prolonged 
survival of mice in a xenograft model
In order to test the effects of Fuc-Liposome-
daunorubicin on tumor growth in vivo, we developed a 
HL-60 xenograft model in mice. These animals were 
treated with Fuc-Liposome-daunorubicin twice a week for 
three weeks (Figure 4A). Tumor growth was significantly 
inhibited by treatment with F50-Liposome-daunorubicin 
compared with no treatment, F0-Liposome-daunorubicin, 
or daunorubicin alone in HL60-bearing mice, suggesting 
that F50-Fuc-Liposome delivered daunorubicin 
specifically and efficiently (Figure 4B; P < 0.01, 4C). In 
hematoxylin-eosin staining of tumor tissues, many viable 
tumor cells were observed in untreated mice (Figure 
4D). In contrast, the number of tumor cells decreased 
in daunorubicin-treated and F0-Liposome-daunorubicin 
treated-mice as compared with untreated mice. However, 
in mice treated with F50-Liposome-daunorubicin, tumor 
cells almost completely disappeared. TUNEL staining 
Figure 2: Introduction of Fuc-liposome-FAM into leukemia cell lines. Fucose was crosslinked to liposomes at 0 (F0), 25 (F25) 
or 50 (F50) µg/ml. HL60 or Molt4 cells were incubated with F0-, F25-, and F50-liposomes-FAM, and after 30 min, cells were analysed by 
fluorescence microscopy A. or by flow cytometry after 2 h incubation B. Experiments were repeated at least three times. NT: no treatment.
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revealed the presence of greater numbers of apoptotic cells 
in tumors treated with F50-Liposome-daunorubicin than 
in controls (Figure 4D), possibly due to the more marked 
accumulation of daunorubicin in tumor tissue.
No adverse effects, including body weight changes, 
attributable to the administration of either D-mannose or 
F50-Liposome-daunorubicin were observed during this 
study (data not shown). Thus, as with in vitro experiments, 
Fuc-Liposome-daunorubicin inhibited tumor growth in 
vivo in a HL-60 xenograft model in mice, possibly by an 
apoptotic mechanism.
Fuc-Liposomes carrying daunorubicin 
suppressed Notch-1 positive AML cells from 
patients
We extended our observations to testing leukemia 
cells derived from AML patients. As shown in Figure 
5 and Tables 1 and 2, 11 cases out of 12 AML patients 
were found to express Notch-1. Furthermore, CD33 
expression by leukemia cells from patients also seemed 
to be compatible with Notch-1 expression. As shown in 
Figure 5A and Supplementary Figure 2, a correlation was 
observed between CD33 and Notch-1 expression at R = 
0.534 (P < 0.001). However, clinical presentation, such as 
prognosis, sex, age, and remission rate did not correlate 
with Notch-1 expression (data not shown). We examined 
the effect of Fuc-Liposome-daunorubicin on leukemia 
patients’ Notch-1 positive and negative cells. As shown 
in Figure 5B, F50-Liposomes containing daunorubicin 
effectively suppressed Notch-1 positive cells but not 
negative cells, indicating that fucose bound-liposomes 
specifically targeted Notch-1 positive leukemia cells 
isolated from patients. However, further investigation 
is required to verify the specificity and efficacy of F50-
Liposomes containing daunorubicin. Thus, fucose-bound 
liposomes carrying daunorubicin suppressed Notch-1 
positive, but not Notch-1 negative, AML cells from 
patients.
DISCUSSION
Presently, more than 20% of AML patients are 
required to undergo salvage therapy, with most having a 
poor prognosis [2]. Therefore, increasing the specificity 
of drugs to leukemia cells should lead to an improvement 
in the prognoses of a considerable proportion of AML 
patients, and minimizing the dose of chemotherapeutic 
agents administered would be expected to lead to their 
reduced toxicity and increased efficacy. The present 
study demonstrated that fucose-bound liposomes carrying 
daunorubicin could effectively target Notch-1/CD33 
Figure 3: Effect of Fuc-liposome-daunorubicin on growth of cultured leukemia cell lines. HL60 or Molt4 cells were 
incubated with F0 (no fucose) or F50 (50 µg/ml fucose) Fuc-liposomes carrying daunorubicin as indicated for 2 h, then washed with PBS 
and incubated for a further 72 h. Viable cells were calculated by BrdU assay as described in Materials and Methods. Cell growth was 
expressed as a percentage of untreated control. Experiments were performed in triplicate and repeated at least three times. *p < 0.05
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Figure 4: Fuc–liposomes carrying daunorubicin suppressed tumor growth in a xenograft model. A. Treatment schedule 
for the HL60 xenograft model. Treatments were administered via tail vein injection to tumor-bearing mice twice a week for three weeks. 
B. Comparison of tumor growth suppression with daunorubicin, F0-liposome-daunorubicin (no fucose), or F50-liposome- daunorubicin 
(50 µg/mL fucose) in HL60-bearing mice with 1 mg/kg daunorubicin used for each treatment. At 1, 4, 8, 11, 15, 18, 22, and 25 days after 
transplantation, tumor volumes were measured. C. Tumor tissue was prepared on day 22 after treatment. D. Hematoxylin eosin (HE) 
staining (upper panel) and TUNEL staining (lower panel) are presented (x 400). n = 6 mice per group *P < 0.01 compared with no treatment 
(NT), daunorubicin (DNR), and F0.
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Figure 5: Effect of Fuc-liposome-daunorubicin on the growth of leukemia cells from patients. A. Expression of CD33/
Notch-1 in Acute leukemia patients’ cells. Leukemia cells derived from patients were analysed by flow cytometry. AML patients (M1, 
M2, M3, M4, M5), ALL patient. B. Effect of Fuc-liposome-daunorubicin on the growth of leukemia cells derived from AML patients. 
AML patient-derived leukemia cells were incubated with Fuc-liposome-daunorubicin for 2 h and washed with PBS. After a further 72 h 
incubation, viable cells were measured by BrdU cell proliferation assay. AML (M1, M2) or ALL patients. Cell growth was expressed as 
a percentage of untreated control. The percentage of CD33/Notch-1 positive cells is demonstrated below. Experiments were performed 
in triplicate and repeated three times. Gray column and black column represented the data treated with 0.1 and 1.0 µM Fuc-liposome-
daunorubicin, respectively. *p < 0.05.
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positive leukemia cells using the intrinsic requirement for 
L-fucose by such cells.
Notch-1 has previously been identified as a 
TAN-specific mutation in T-ALL patients [3]. Recent 
investigations have highlighted that Notch-1 shows a 
variety of roles in maintaining homeostasis in human 
cells and also plays an important role in carcinogenesis 
[5]. Such findings demonstrated that Notch-1 signaling 
maintained tumor growth, antiapoptotic signaling, 
epithelial-mesenchymal transition for cancer cell 
metastasis, angiogenesis, and cancer stem cell survival 
[5]. Our strategy to target cancer cells, which actively 
take up L-fucose to produce fucosylated proteins such 
as sialylated antigens and growth factors in response to 
Table 1: Patient characteristics
No Diagnosis Gender Age Treatment
1 AML (M1) M 81 BSC
2 AML (M2) F 57 IDR/AraC
3 AML (M2) M 66 IDR/AraC
4 ALL F 71 CY/DNR/VCR/L-ASP/PSL
5 AML (M2) M 64 IDR/AraC
6 AML (M2) M 44 BMT
7 AML (M3) M 49  
8 AML (M2) M 66 IDR/AraC
9 AML(M4) F 43 IDR/AraC
10 AML (M2) F 21 BMT
11 AML(M4) M 64 BMT
12 AML (M6) M 64 BMT
13 AML (M2) F 80 BSC
AML: acute myelogenous leukemia, ALL: acute lymphoblastic leukemia
BSC: best supportive care, IDR: idarubicin, AraC: Cytarabine, PSL: prednisolone, CY: cyclophosphamide, DNR: 
daunorubicin, VCR: vincristine, L-ASP: L-asparaginase, BMT: bone marrow transplantation
Table 2: Expression of Notch1 and/or CD33 in leukemia patients
No Diagnosis CD33 x Notch1 Notch1 CD33
1 AML (M1) 38.53 48.56 68.84
2 AML (M2) 32.83 33.64 97.13
3 AML (M2) 24.27 54.5 33.81
4 ALL 1.61 11.76 14.41
5 AML (M2) 16.68 29.8 22.75
6 AML (M2) 24.13 29.34 42.26
7 AML (M3) 10.42 16.91 15.93
8 AML (M2) 27.59 39.2 57.69
9 AML(M4) 70.54 72.51 92.54
10 AML (M2) 12.65 26.78 19.49
11 AML(M4) 36.75 37.46 97.3
12 AML (M6) 33.87 55.73 37.81
13 AML (M2) 7.65 15.44 37.55
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Notch-1 activation, can be utilized for killing Notch-
1-expressing cancer cells in the same manner [16]. As 
described in this report, our drug delivery system has the 
potential to specifically target cancer cells with reduced 
toxicity and high efficacy.
We did not find any adverse events when 
fuc-liposomes carrying an anti-cancer drug were 
administered twice a week to tumor-bearing mice, 
suggesting that its non-specific distribution to normal 
tissue was very low due to a high accumulation in 
tumors. The positive-targeting of cancer cells by a 
specific molecule using antibody-bound liposomes 
had been expected to be less toxic due to its specific 
distribution; however, this strategy presented several 
obstacles. Antigens targeted by modified liposomes are 
not specific to tumor cells, and may be competed with 
by antigens existing in the blood, resulting in damage to 
normal tissue or cells. Gemtuzumab ozogamicin (GO) 
was developed using this concept of directly targeting 
AML cells, and has been shown to be effective in 
relapsed AML patients [21]. However, remission rates 
have typically not exceeded 25% [22], indicating that 
targeting CD33 in the treatment of AML patients also 
requires improvements in strategy.
In regard to this issue, fucose-bound liposomes 
accumulated only in the liver; this distribution was 
eradicated by the administration of D-mannose, indicating 
that tissues other than liver do not actively take up 
L-fucose under normal conditions. In normal bone marrow 
cells, Notch-1 expression has been reported to be very low 
compared with leukemia cells [23, 24]. This phenomenon 
has also been confirmed in our previous report [11]. Thus, 
fucose-bound liposomes carrying anticancer drugs may be 
less toxic than any other drug delivery system already in 
clinical use.
It has been shown that cancer stem cells can self-
renew symmetrically or can divide asymmetrically to 
produce daughter cells, which continue to proliferate to 
sustain tumor growth. Notch-1 has been demonstrated 
to play an important role in regulating cancer stem cells 
[25], suggesting that fucose-bound liposomes could also 
target these cells. Indeed, we found that pancreatic cancer 
stem-like cells expressing CD24/CD44 were targeted 
by L-fucose liposomes (data not shown). These results 
suggest that the majority of AML cells, including cancer 
stem cells, that exist during relapse or are resistant to 
conventional chemotherapy, may effectively be treated by 
L-fucose liposome therapy.
The Notch signaling pathway is also involved in the 
acquisition of drug resistance against chemotherapeutic 
agents, and in the activation of anti-apoptotic pathways in 
cancer cells. Molecules involved in these pathways have 
been shown to activate the PI3K-AKT axis and NFκB, 
as demonstrated by the use of a γ-secretase (GSI), and 
Notch-1 inhibitors in pancreatic, colorectal and breast 
cancers [26–28]. Thus, it might be expected that drug 
resistant clones, including Notch-expressing cells, may be 
effectively eradicated by a single administration of fucose-
bound liposomes, resulting in early remission for patients 
with AML.
It is noteworthy that Notch-1-expressing AML cells 
were found in 90% of patients we examined in our study. 
However, the role of Notch-1 in AML progression still 
remains unclear. For instance, when GSI is administered 
to AML patients, the efficacy of this drug is minimal, 
indicating that Notch-1 is not a major player in driving 
AML clones. Recently, it has been shown that Notch 
mediates growth arrest and apoptosis in AML cells 
via activation of Hairy/Enhancer of Split 1 (HES1), 
suggesting the development of Notch agonists as a new 
therapy [24].
As we have previously demonstrated, L-fucose-
mediated cell-targeting is a promising new therapeutic 
strategy for cancer treatment [11]. Herein, we show 
that the expression of CD33 and Notch-1 correlate in 
the same leukemia cell lines, and that Notch-1 positive 
leukemia cells are targeted by L-fucose-bound liposomes, 
Fuc-Liposome-daunorubicin particles were found to 
inhibit the growth of Notch-1 positive cells in vitro and 
in a mouse xenograft model, and suppressed Notch-1 
positive, but not Notch-1 negative, AML cells derived 
from patients. Our results suggest that fucose-targeting 
therapy could be effective in increasing the survival of 
patients with AML.
MATERIALS AND METHODS
Materials
Daunorubicin was purchased from Santa Cruz 
(Dallas, TX, USA). Dipalmitoylphosphatidylcholine 
(DPPC), cholesterol (Chol), dicetyl phosphate (DCP), 
sodium cholate hydrate (cholic acid), human serum 
albumin (HSA), sodium periodate, deuterium oxide 
(D2O), sodium hexachloroplatinate, tris(hydroxymethyl)
aminomethane (Tris), and L-fucose were purchased 
from Sigma (St. Louis, MO, USA). Ganglioside was 
purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). Dipalmitoylphosphatidylethanolamine (DPPE) 
was purchased from Alexis (Plymouth Meeting, PA, 
USA). N-tris(hydroxymethyl)methyl-3-amino-propane 
sulfonic acid (TAPS) and n-(2-hydroxyethyl) piperazine-
n’-(2-ethanesulfonic) acid were purchased from Doujin 
Chemical (Kumamoto, Japan). Sodium cyanoborohydrate 
was purchased from Aldrich (Milwaukee, WI, USA). BS3 
and 3,3-dithiobis(sulfosuccinimidyl propionate) (DTSSP) 
were purchased from Pierce Biotechnology (Rockford, IL, 
USA). Cholesterol E-test Wako was purchased from Wako 
(Osaka, Japan).
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Patient cells and cell lines
Acute leukemia cells were obtained from patients 
after informed consent was obtained in accordance 
with the Declaration of Helsinki and institutional 
ethics committee. HL60, RPMI8226, KG1 and MOLT4 
cells were obtained from the RIKEN Bioresource 
center (Tsubuka, Japan). The cells were cultured in 
RPMI 1640 (Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% FBS, L-glutamine and 1% 
penicillin-streptomycin. These cells were authenticated 
by cytogenetics in 2013.
Reverse transcription-polymerase chain reaction 
(RT-PCR)
Total RNA (1 µg) was reverse transcribed with a 
Superscript III first strand synthesis kit (Life Technologies) 
using random hexamers (100 pM) according to the 
manufacturer’s instructions. cDNAs were amplified for 
25 to 30 cycles using Pfu Turbo (Stratagene, La Jolla, CA, 
USA), 0.2 mM of each dNTP and 100 pM each primer. 
Each cycle consisted of 30 sec at 95°C, 30 sec at 55°C and 
60 sec at 72°C. The sequences targeting human POFUT 
were as follows: POFUT: forward, 5’- TGA AGG AAG 
GAA ACC CCT TT -3', reverse, 5’- TCT CCC GTC TTC 
ACC ATT TC -3': internal standard ß-actin: forward, 5′-
GCT CGT CGT CGA CAACGG CTC- 3′; reverse, 5′-
CAA ACA TGC TCT GGG TCA TCT TCT- 3′.
Preparation of FAM and daunorubicin 
encapsulated in liposomes
Preparation of FAM carrying liposomes has 
been described previously [11]. Briefly, DPPC, Chol, 
ganglioside, DCP, and DPPE were mixed at different 
molar ratios, and cholic acid added to facilitate micelle 
formation. The mixture was dissolved in methanol/
chloroform (1:1, v/v), and the solvent was evaporated 
at 37°C to produce a lipid film, which was dried under 
vacuum. For the daunorubicin preparation, a HSA solution 
(HSA 20 mg/mL, 0.2 N NaOH) containing daunorubicin 
(20 mg/mL) was added to the lipid film and sonicated to 
obtain uniform micelles, which were then ultrafiltered 
(molecular weight cutoff 10 kD; Amicon PM10, Millipore, 
Billerica, MA, USA). Hydrophilization treatment and 
L-fucose conjugation on the surface of liposomes were 
carried out by methods modified from Yamazaki et al. 
[29]. Aminated L-fucose was conjugated to the liposome 
surface using DTSSP as described previously.
Physicochemical characterization of  
Fuc-Liposome-daunorubicin
The average particle size and zeta-potential of 
liposomes were measured as described previously[11]. 
The lipid concentrations of Liposome-daunorubicin 
and Fuc-Liposome-daunorubicin were measured 
using a Cholesterol E-test Wako Kit as described 
previously[11].
Measurement of daunorubicin and calculation of 
daunorubicin concentration and encapsulation 
efficiency
The concentration of daunorubicin was 
measured by absorbance at 485 nm. In brief, Fuc-
Liposome-daunorubicin was diluted 1,000-fold with a 
methanol:chloroform (1:1) solution, and the concentration 
of daunorubicin was determined by absorbance at 485 nm. 
A calibration curve, with daunorubicin concentrations in 
the range of 625 – 5000 ng/mL was run before the analysis 
of each sample type.
Encapsulation efficiency (%) = (Amount of 
daunorubicin in liposomes/Initial amount of daunorubicin) 
× 100
Daunorubicin to lipid weight ratio = Daunorubicin 
concentration (mg/mL)/Lipid concentration (mg/mL)
Flow cytometry analysis
Cells (1 x 105) were incubated with Fuc-Liposome-
FAM or Liposome-FAM (lipid concentration: 4 µg/mL) 
for 2 h. For the blocking assay, 1 x 105 cells were treated 
with L-fucose for 30 min prior to adding Fuc-Liposome-
FAM or Liposome-FAM. The mean fluorescence 
intensity (MFI) was assessed on a FACScalibur with 
CellQuest software (Becton Dickinson, Franklin Lakes, 
NJ, USA). For the detection of CD33 and Notch-1 
expression, cell line samples (5 x 105 cells each) were 
incubated with isotypic control, allophycocyanin (APC)-
conjugated anti-Notch-1 antibody (R & D systems, 
Minneapolis, MN, USA) or FITC-conjugated anti-CD33 
antibody (Miltenyl Biotec Bergisch Gladbach, Germany) 
on ice for 30 min. After washing in PBS/0.05% BSA, 
the cells were analyzed by flow cytometry (Beckton 
Dickinson).
Intracellular distribution analysis of FAM
Cells were plated in Lab-Tek chambered 
coverglasses at 1 x 104 cells/chamber. Fuc-Liposome-
FAM or Liposome-FAM was added to cells at a final 
FAM concentration of 4 ng/ml. Cells were cultured in 
complete medium for 30 min, after which the medium 
was replaced with fresh medium. At 30 min and 2 h 
post-treatment, cells were washed twice with PBS and 
fixed with 4% paraformaldehyde for 15 min at room 
temperature. After fixation, cells were washed three times 
with PBS and exposed to Prolong Gold Antifade Reagent 
with DAPI (Life Technologies) for 10 min to stain nuclei. 
The subcellular localization of FAM was assessed by 
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fluorescence microscopy (BZ-8000; Keyence, Osaka, 
Japan).
Cell proliferation assay
Human leukemia cell lines (2 x 104 cells/well) 
were seeded into 24-well plates, and cultured for one 
day in medium supplemented with 10% fetal bovine 
serum, 5% L-glutamine, and 1% antibiotics. Cells were 
then incubated with different doses of Fuc-Liposome-
daunorubicin. After 2 h incubation, cells were washed 
twice with PBS and finally resuspended in medium 
containing serum and antibiotics. After culture for 72 h, 
a BrdU cell proliferation assay reagent (Cell Signaling, 
Boston, MA, USA) was added and the assay performed 
according to manufacturer’s instructions. Experiments 
were performed in triplicate and repeated at least twice.
AML xenograft model and treatment schedule
In a subcutaneous model, 2 x 106HL60 cells were 
inoculated to create a dorsal lesion (mice aged 4 to 6 
weeks) and each was allowed to grow into a tumor 5 mm 
in diameter. Tumor-bearing mice were randomly assigned 
to one of the following groups (n = 6 mice per group): 
no treatment, daunorubicin (1 mg/kg), F0-Liposome-
daunorubicin (1 mg/kg), and F50-Liposome-daunorubicin 
(1 mg/kg). Treatments were administered through tail 
vein injection with a single dose of 100 μl of the above-
mentioned drugs, twice a week for three weeks. At 4, 8, 
11, 15, 18, 22 and 25 days after transplantation, tumor 
volumes were measured. For D-mannose pre-treatment in 
all in vivo experiments, 5 mg of D-mannose was injected 
through a tail vein 5 min prior to the administration of 
agents as described previously [11].
These studies were carried out according to the 
Guide for the Care and Use of Laboratory Animals of 
the National Institutes of the Health. The protocols were 
approved by the Committee on the Ethics of Animal 
Experiments of Sapporo Medical University. All surgery 
was performed under sodium pentobarbital anesthesia, 
and all efforts were made to minimize suffering. All mice 
underwent euthanasia when tumor volumes reached 20 
mm in diameter.
Statistics
Results are presented as mean ± standard deviation 
(SD) for each sample. Differences between the two 
groups were examined by unpaired and paired t tests. 
If two groups could not be considered to be of equal 
variance, a t test with Welch’s correction was performed. 
The correlation analysis was tested by Pearson’s product-
moment correlation coefficient. All statistical analyses 
were performed using JMP, version 5.0 for Windows 
(SAS, Cary, NC, USA). Results were considered 
statistically significant when P < 0.05.
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